KR960037650A - 선택적 트롬빈 억제제 - Google Patents

선택적 트롬빈 억제제 Download PDF

Info

Publication number
KR960037650A
KR960037650A KR1019950043957A KR19950043957A KR960037650A KR 960037650 A KR960037650 A KR 960037650A KR 1019950043957 A KR1019950043957 A KR 1019950043957A KR 19950043957 A KR19950043957 A KR 19950043957A KR 960037650 A KR960037650 A KR 960037650A
Authority
KR
South Korea
Prior art keywords
propionamide
cyclopentyl
methyl
phenyl
naphthylsulfonylamino
Prior art date
Application number
KR1019950043957A
Other languages
English (en)
Other versions
KR0173034B1 (ko
Inventor
황상열
오영수
김상수
홍성원
윤미경
이구
신유승
Original Assignee
성재갑
주식회사 Lg 화학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성재갑, 주식회사 Lg 화학 filed Critical 성재갑
Priority to KR1019950043957A priority Critical patent/KR0173034B1/ko
Publication of KR960037650A publication Critical patent/KR960037650A/ko
Application granted granted Critical
Publication of KR0173034B1 publication Critical patent/KR0173034B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 경구투여용으로 사용하는 경우에도 효과가 있는 하기 일반식(Ⅰ)의 신규한 선택적 트롬빈 억제제, 그의 제조방법 및 이 화합물을 유효성분으로 함유하는 트롬빈 억제용 약제학적 조성물에 관한 것이다.
상기 식에서, R1은 아릴 또는 아릴옥시에 의해 치환된 아세틸을 나타내거가, 치환되거나 비치환된 아릴에 의해 치환된 술포닐을 나타내고, R2및 R3는 각각 독립적으로 수소, 사이클로알킬, 아르알킬옥시 또는 하이드록시를 나타내거나, 하이드록시에 의해 치환되거나 비치환된 저급알킬을 나타내고, R4및 R5는 각각 독립적으로 수소, 저급알킬 또는 아미노를 나타낸다.

Description

선택적 트롬빈 억제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(Ⅰ)로 표시되는, 화합물, 약제학적으로 허용되는 그의 염, 수화물, 용매화물 및 이성체.
    상기 식에서, R1은 아릴 또는 아릴옥시에 의해 치환된 아세틸을 나타내거가, 치환되거나 비치환된 아릴에 의해 치환된 술포닐을 나타내고, R2및 R3는 각각 독립적으로 수소, 사이클로알킬, 아르알킬옥시 또는 하이드록시를 나타내거나, 하이드록시에 의해 치환되거나 비치환된 저급알킬을 나타내고, R4및 R5는 각각 독립적으로 수소, 저급알킬 또는 아미노를 나타낸다.
  2. 제1항에 있어서, R1이 나프틸 또는 나프틸옥시에 의해 치환된 아세틸을 나타내거가 저급알킬, 저급 알콕시 및 디알킬아미노로 구성된 그룹중에서 선택된 1 내지 4개의 치환체에 의해 치환되거나 비치환된 나프틸 또는 페닐에 의해 치환된 술포닐을 나타내며 ; R2및 R3는 각각 독립적으로 C3-6사이클로알킬, 벤질옥시 또는 하디드록시에 의해 치환되거나 비치환된 저급알킬, 또는 하이드록시를 나타내고 ; R4및 R5는 각각 독립적으로 수소, 메틸 또는 아미노를 나타내는 화합물.
  3. 제2항에 있어서, (S)-N-사이클로펜틸-N-메틸-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-부틸-N-메틸-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-프로필-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-(2-벤질옥시에틸)-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-부틸-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-에틸-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-메틸-3〔4-(1-메틸아미디노)페닐〕-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-메틸-3-〔4-(1,1-디메틸아미디노)페닐〕-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-메틸-3-(4-아미드라조노페닐)-2-(4-메톡시-2,3,6-트리메틸벤젠술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-하이드록시-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-(2-하이드록시에틸)-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로펜틸-N-메틸-3-〔4-(1-메틸아미디노)페닐〕-2-(4-메톡시-2,3,6-트리메틸벤젠술포닐아미노)프로피온아미드, (S)-N,N-디메틸-3-〔4-(1-메틸아미노)페닐〕-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N,N-디메틸-3-〔4-(1-메틸아미노)페닐〕-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로헥실-N-메틸-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-N-사이클로프로필-N-메틸-3-(4-아미드라조노페닐)-2-(2-나프틸술포닐아미노)프로피온아미드, (S)-3-〔(4-아미드라조노)-페닐〕-N-사이클로펜틸-N-메틸-2-(2-나프탈렌-1-일-아세틸아미노)-프로피온아미드, (S)-3-〔(4-아미드라조노)-페닐〕-N-사이클로펜틸-N-메틸-2-(5-디메틸아미노-나프탈렌-1-술포닐아미노)-프로피온아미드, (S)-3-〔(4-아미드라조노)-페닐〕-N-사이클로펜틸-N-메틸-2-(5-메톡시-나프탈렌-1-술포닐아미노)-프로피온아미드, (S)-2-〔(4-아미드라조노)-페닐〕-N-사이클로펜틸-N-메틸-2-(6,7-디메톡시-나프탈렌-2-술포닐아미노)-프로피온아미드, (S)-3-〔(4-메탈아미디노)-페닐〕-N-사이클로펜틸-N-메틸-2-(5-디메탈아미노-나프탈렌-1-술포닐아미노)-프로피온아미드, (S)-3-〔(4-아미드라조노)-페닐〕-N-사이클로펜틸-N-메틸-2-(나프탈렌-1-술포닐아미노)-프로피온아미드, (S)-3-〔(4-아미드라조노)-페닐〕-N-사이클로펜틸-N-메틸-2-〔2-(나프탈렌-1-일-옥시)아세틸아미노〕-프로피온아미드, 및 (S)-3-〔(4-아미드라조노)-페닐〕-N-사이클로펜틸-N-메틸-2-〔2-(나프탈렌-2-일-옥시)아세틸아미노〕-프로피온아미드로 구성된 그룹중에서 선택된 화합물.
  4. 하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시킴을 특징으로 하여 하기 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기 식에서, R1, R2, R3, R4및 R5는 제1항에서 정의한 바와 같다.
  5. 제4항에 있어서, 반응을 용매의 존재하에서 수행함을 특징으로 하는 방법.
  6. 제5항에 있어서, 용매가 메탄올인 방법.
  7. 제4항에 있어서, 일반식(Ⅱ)의 화합물이 하기 일반식〔5〕의 화합물에 요오드화메탄을 이용하여 메틸기를 도입시킴으로써 제조된 것인 방법.
    상기 식에서 R1, R2및 R3는 제1항에서 정의한 바와 같다.
  8. 제7항에 있어서, 일반식〔5〕의 화합물이 하기 일반식〔4〕의 화합물을 피리딘 용매 및 트리메틸아민 존재하에 황화수소를 포화시켜 반응시킴으로써 제조된 것인 방법.
    상기 식에서 R1, R2및 R3는 제1항에서 정의한 바와 같다.
  9. 제1항 내지 3항중의 어느 한 항에 정의된 화합물을 유효성분으로 함유하는 트롬빈 억제용 약제학적 조성물.
  10. 제9항에 있어서, 경구형 제제로 제형화됨을 특징으로 하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950043957A 1995-04-28 1995-11-27 선택적 트롬빈 억제제 KR0173034B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950043957A KR0173034B1 (ko) 1995-04-28 1995-11-27 선택적 트롬빈 억제제

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR95-10383 1995-04-28
KR19950010383 1995-04-28
KR1019950043957A KR0173034B1 (ko) 1995-04-28 1995-11-27 선택적 트롬빈 억제제
CA002188690A CA2188690C (en) 1995-04-28 1996-10-23 Selective thrombin inhibitors
PCT/KR1996/000184 WO1997049673A1 (en) 1995-04-28 1996-10-28 Selective thrombin inhibitors
AU70481/96A AU696380B2 (en) 1995-04-28 1996-10-29 Selective thrombin inhibitors
NZ299659A NZ299659A (en) 1995-04-28 1996-10-29 Amidine derivatives; compounds, preparation and medicaments with anti-thrombin activity

Publications (2)

Publication Number Publication Date
KR960037650A true KR960037650A (ko) 1996-11-19
KR0173034B1 KR0173034B1 (ko) 1999-03-30

Family

ID=27507193

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950043957A KR0173034B1 (ko) 1995-04-28 1995-11-27 선택적 트롬빈 억제제

Country Status (11)

Country Link
US (1) US5747535A (ko)
EP (1) EP0739886B1 (ko)
JP (2) JP2844329B2 (ko)
KR (1) KR0173034B1 (ko)
AT (1) ATE251146T1 (ko)
AU (1) AU696380B2 (ko)
CA (1) CA2188690C (ko)
DE (1) DE69630160T2 (ko)
ES (1) ES2202385T3 (ko)
NZ (1) NZ299659A (ko)
WO (1) WO1997049673A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100441635B1 (ko) * 1997-04-03 2006-01-12 주식회사 엘지생명과학 경구투여가가능한선택적트롬빈억제제
KR19980076024A (ko) * 1997-04-04 1998-11-16 성재갑 경구투여가 가능한 선택적 트롬빈 억제제
KR100361827B1 (ko) * 1997-04-07 2003-01-24 주식회사 엘지생명과학 트롬빈 억제제로서 유용한 헤테로사이클릭알라닌 유도체
WO1998054164A1 (en) * 1997-05-30 1998-12-03 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
KR100373374B1 (ko) * 1997-08-26 2003-10-22 주식회사 엘지생명과학 트롬빈 억제제의 제조방법, 이를 위한 신규한 중간체 및 그의 제조방법
EP0921116B1 (de) * 1997-12-04 2003-06-18 F. Hoffmann-La Roche Ag N-(4-carbamimido-phenyl)-glycinamidderivate
EP1054005A4 (en) 1998-02-05 2003-02-05 Takeda Chemical Industries Ltd SULFAMIDE DERIVATIVES, THEIR PRODUCTION PROCESS AND THEIR USE
KR100406632B1 (ko) * 1998-06-12 2004-04-03 주식회사 엘지생명과학 트롬빈억제제의새로운제조방법
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
TR200101744T2 (tr) * 1998-12-14 2001-12-21 F. Hoffmann-La Roche Ag Fenilglisin türevleri.
AR023819A1 (es) 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
US6710061B2 (en) 2001-03-09 2004-03-23 Ortho-Mcneil Pharamceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
JP2004520438A (ja) 2001-03-09 2004-07-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド セリンプロテアーゼインヒビターとしてのアミノピロリジンスルホンアミド
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
CH695999A5 (de) 2002-02-28 2006-11-15 Wilex Ag Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
ES2348942T3 (es) 2002-12-11 2010-12-17 Bayer Schering Pharma Aktiengesellschaft Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato.
WO2005033068A1 (en) * 2003-10-06 2005-04-14 Oy Juvantia Pharma Ltd Somatostatin receptor 1 and/or 4 selective agonists and antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
CA2609161A1 (en) * 2005-05-18 2006-11-23 Siegfried Wurster Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
CN102702105A (zh) * 2005-12-30 2012-10-03 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
CN117083052A (zh) 2021-02-16 2023-11-17 帝斯曼知识产权资产管理有限公司 用于治疗皮肤老化的lrat抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201863A (en) * 1974-11-08 1980-05-06 Mitsubishi Chemical Industries, Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
SE8203887D0 (sv) * 1982-06-23 1982-06-23 Kabivitrum Ab Nya trombininhiberande foreningar
AU1354292A (en) * 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
AU5878194A (en) * 1993-02-10 1994-08-29 Pentapharm Ag Piperazides of substituted phenylalanine derivates as thrombin inhibitors

Also Published As

Publication number Publication date
CA2188690C (en) 2003-07-29
ES2202385T3 (es) 2004-04-01
AU7048196A (en) 1998-05-07
AU696380B2 (en) 1998-09-10
JP2844329B2 (ja) 1999-01-06
DE69630160D1 (de) 2003-11-06
KR0173034B1 (ko) 1999-03-30
ATE251146T1 (de) 2003-10-15
EP0739886B1 (en) 2003-10-01
WO1997049673A1 (en) 1997-12-31
CA2188690A1 (en) 1998-04-23
EP0739886A2 (en) 1996-10-30
US5747535A (en) 1998-05-05
NZ299659A (en) 1997-12-19
EP0739886A3 (en) 1999-01-27
JPH115780A (ja) 1999-01-12
JPH08301833A (ja) 1996-11-19
DE69630160T2 (de) 2004-08-26

Similar Documents

Publication Publication Date Title
KR960037650A (ko) 선택적 트롬빈 억제제
GB1422263A (en) 4-phenyl-piperidine compounds
DK0915866T3 (da) Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
KR860003210A (ko) 알킬설폰 아미도 페닐알킬 아민의 제조 방법
KR920006314A (ko) 아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP1106179A3 (en) Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
KR880011135A (ko) 콜린성계 상에 작용하는 신규 티아졸 유도체, 그의 제조방법 및 약학 조성물
KR900011760A (ko) 신규한 벤조 피란 유도체, 그 제조 및 상기 유도체를 함유하는 제약학적 조성물
BR9612099A (pt) Processo para preparar um composto derivado de piperidina, regioisÈmero, processo para preparar um regioisÈmero, derivado de ácido 4-( alfa,alfa, di-substuìdo) toluico e 4- (alfa, alfa-di-não substitìdo) toluico.
EP1172361A4 (en) SULFONAMIDE DERIVATIVES HAVING OXADIAZOLE CORES
KR840007596A (ko) 유기인 유도체의염의 제조방법
DK0674621T3 (da) Enantiomerer af carbazolderivater som 5-HT1-lignende agonister
ES557663A0 (es) Un procedimiento para la sintesis de derivados de imidazol.
KR850001184A (ko) 1,5-벤조티아제핀 유도체의 제조방법
KR830010072A (ko) 아미디노 피페리딘 유도체의 제조방법
GB1459564A (en) Alkylphenyl benzopyrans
WO1997031016A3 (en) New inhibitors of sh2-mediated processes
YU52498A (sh) UPOTREBA 2-ARILBENZO (b) TIOFENA ZA DOBIJANJE LEKA
AU6602594A (en) New phosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them
KR860001048A (ko) 플루오로알릴아민 유도체의 제조방법
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR970074764A (ko) 불소화된 비타민 d₃ 동족체
KR850004460A (ko) 인돌의 제조방법
BR9400817A (pt) Processo para preparar derivados de sulfoniluréia, processo para preparar derivados de sulfonilcloreto, composto hidróxido de 1-(((pirazolesulfonil)amino)carbonil) piridínio e processo para preparar compostos
KR930007880A (ko) 비스(페닐)에탄 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060915

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee